Foundation to Promote Research into Functional Vitamin B12 Deficiency, Bergen, Norway Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
1998
NCT00266487
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (3)

cyanocobalamin (berocca) (2 trials)

folic acid (2 trials)

pyridoxine (2 trials)

Drugs in Other Trials (2)

hydroxocobalamin (cyanokit) (1 trial)

methylcobalamin (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Infarction (Phase 3)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 3)

Stroke (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 5